Clarametyx Biosciences’ Post

🦠🧫 Addressing antimicrobial resistance to stop sepsis 🥼 ⌚ Every 2.8 seconds, someone, somewhere in the world dies from sepsis. Antimicrobials are crucial for treating sepsis, but the growing crisis of antimicrobial resistance threatens the efficacy of antimicrobial therapy. 🔬🧪 🗺 This World Sepsis Day, learn how evidence-based diagnostics, used in combination with antimicrobial stewardship, can help prevent sepsis: https://lnkd.in/gT-w2yYv #QIAGEN #WorldSepsisDay

🦠 In our recent #ExpertInsights article, our VP of Clinical Research, Emily Friedland, delves into the FDA's recent decision to reclassify certain infectious disease IVDs from Class III to Class II. This regulatory shift is set to have a significant impact on the #IVD industry, particularly for those in the infectious disease and companion diagnostics sectors. In her article, Emily provides an overview analysis of the implications of this reclassification and offers guidance for developers to align their processes accordingly. Don't miss out on this valuable insight! https://hubs.ly/Q02G2rzb0 #DCNDx #FDA #Regulatory #ClinicalStudies #InfectiousDisease #Diagnostics

🦠 In our recent #ExpertInsights article, our VP of Clinical Research, Emily Friedland, delves into the FDA's recent decision to reclassify certain infectious disease IVDs from Class III to Class II. This regulatory shift is set to have a significant impact on the #IVD industry, particularly for those in the infectious disease and companion diagnostics sectors. In her article, Emily provides an overview analysis of the implications of this reclassification and offers guidance for developers to align their processes accordingly. Don't miss out on this valuable insight! https://hubs.ly/Q02G2L980 #DCNDx #FDA #Regulatory #ClinicalStudies #InfectiousDisease #Diagnostics

PRODUCT NAME: Heli-Rox 750mg GENERIC NAME: Cefuroxime 750 mg Sterilized PACK SIZE: 1’s SUMMARY: It is a second generation cephalosporin anti biotic used to treat and prevent a number of bacterial infections. These include pneumonia, meningitis, ottits-media, sepsis, urinary tract infections and lyme disease MODE OF ACTION: It acts by inhibition of bacterial cell wall synthesis it has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of gram negative and gram positive bacteria

🦠 In our recent #ExpertInsights article, our VP of Clinical Research, Emily Friedland, delves into the FDA's recent decision to reclassify certain infectious disease IVDs from Class III to Class II. This regulatory shift is set to have a significant impact on the #IVD industry, particularly for those in the infectious disease and companion diagnostics sectors. In her article, Emily provides an overview analysis of the implications of this reclassification and offers guidance for developers to align their processes accordingly. Don't miss out on this valuable insight! https://hubs.ly/Q02ryz5h0 #DCNDx #FDA #Regulatory #ClinicalStudies #InfectiousDisease #Diagnostics

🦠 In our recent #ExpertInsights article, our VP of Clinical Research, Emily Friedland, delves into the FDA's recent decision to reclassify certain infectious disease IVDs from Class III to Class II. This regulatory shift is set to have a significant impact on the #IVD industry, particularly for those in the infectious disease and companion diagnostics sectors. In her article, Emily provides an overview analysis of the implications of this reclassification and offers guidance for developers to align their processes accordingly. Don't miss out on this valuable insight! https://hubs.ly/Q02ryq4m0 #DCNDx #FDA #Regulatory #ClinicalStudies #InfectiousDisease #Diagnostics

Bio-Zil (Cefixime): Experience Faster Recovery with Reduced Resistance Risk. Bio-Zil (cefixime) offers a path to faster recovery from bacterial infections. This advanced formulation leverages the power of cefixime to deliver rapid symptom relief and a renewed sense of well-being. Engineered to maximize efficacy, Bio-Zil also minimizes the risk of resistance development, promoting a more hopeful future for patients battling infections.

🦠 In our recent #ExpertInsights article, our VP of Clinical Research, Emily Friedland, delves into the FDA's recent decision to reclassify certain infectious disease IVDs from Class III to Class II. This regulatory shift is set to have a significant impact on the #IVD industry, particularly for those in the infectious disease and companion diagnostics sectors. In her article, Emily provides an overview analysis of the implications of this reclassification and offers guidance for developers to align their processes accordingly. Don't miss out on this valuable insight! https://hubs.ly/Q02rywQd0 #DCNDx #FDA #Regulatory #ClinicalStudies #InfectiousDisease #Diagnostics

Putting a face on the 'invisible threat' of antimicrobial resistance   Mallory Smith's story is a powerful reminder of the devastating impact of antimicrobial resistance (AMR) on individuals and their families. Diagnosed with cystic fibrosis at a young age, Mallory faced the added burden of battling Burkholderia cepacia, a highly resistant and life-threatening bacterial infection. Despite the relentless challenges, including deteriorating lung function and frequent hospitalizations, Mallory never let her condition define her. Her courage and determination to live a full and meaningful life, even as the bacteria became resistant to every available treatment, are truly inspiring.    Mallory's story, and the advocacy of her mother, Diane Shader Smith, bring a human face to the critical issue of AMR, reminding us all of the urgent need to develop new, effective treatments to combat these deadly pathogens. At Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), stories like Mallory's fuel our determination to innovate and find solutions that can help prevent others from experiencing such profound loss.   https://lnkd.in/ehdBfFgS   #AcurxPharmaceuticals #ClinicalTrials #InfectiousDiseases #CDifficile

🦠 In our recent #ExpertInsights article, our VP of Clinical Research, Emily Friedland, delves into the FDA's recent decision to reclassify certain infectious disease IVDs from Class III to Class II. This regulatory shift is set to have a significant impact on the #IVD industry, particularly for those in the infectious disease and companion diagnostics sectors. In her article, Emily provides an overview analysis of the implications of this reclassification and offers guidance for developers to align their processes accordingly. Don't miss out on this valuable insight! https://hubs.ly/Q02ryrRN0 #DCNDx #FDA #Regulatory #ClinicalStudies #InfectiousDisease #Diagnostics